maintains its overweight recommendation
https://www.marketscreener.com/quote/stock/VERTEX-PHARMACEUTICALS-IN-11321/
Tuesday, November 7, 2023
Calliditas Interim Report January - September 2023
The Lancet publication of full Phase 3 data set
In August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd, published in The Lancet and we are looking forward to a potential full approval of TARPEYO for treatment of IgA Nephropathy, for which the PDUFA date is December 20, 2023.
https://finance.yahoo.com/news/calliditas-interim-report-january-september-063200840.html
LEQEMBI® update from Eisai's investor presentation of their quarterly
BioArctic AB's (publ) (NASDAQ; BIOA B) (Stockholm: BIOA B) partner Eisai today held a presentation on the second quarter of Eisai's fiscal year, ending March 2024. In addition to presenting sales numbers of 0.4 billion yen for LEQEMBI for the period, Eisai also stated the following;
- The launch of LEQEMBI in the U.S. is progressing as planned and the company reiterated their expectation that 10,000 patients will be on LEQEMBI by the end of March 2024
- The number of neurologists or other Alzheimer disease (AD) specialists who are ready to diagnose, treat and monitor patients on LEQEMBI has increased from approximately 1,400 in June to 2,500 in October
- 60% of the top 100 Integrated Delivery Networks (IDN[1]) in the U.S. have now approved LEQEMBI, which means the treatment is available within their health system
- Eisai aims to achieve 10 billion yen (M 700 SEK in today's currency) level revenue from LEQEMBI in their fiscal year 2023, ending March 2024 (not to be seen as guidance). BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region.
BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
Monday, November 6, 2023
WuXi Biologics' medical research unit eyes up to $471 mln in Hong Kong IPO
China-headquartered WuXi XDC, the contract medical researching unit of WuXi Biologics (Cayman), said on Tuesday it intended to raise up to HK$3.68 billion ($470.56 million) in one of Hong Kong's top initial public offerings (IPO) this year.
The company, which is a joint venture between WuXi Biologics and WuXi STA that provides end-to-end contract services covering antibodies and other biologics intermediates, will issue 178.4 million shares priced at a maximum of HK$20.60 each, according to the company's regulatory filing.
In July, parent WuXi Biologics revealed its intentions to spin-off Wuxi XDC and initiate a separate listing for the arm.
Wuxi Biologics said the separate listing would enable the unit to serve as an independent platform that would continue to focus on the company's global contract research, development, and manufacturing organization businesses, highlighting the benefits of better allocation of capital and resources if the IPO goes through.
"The spin-off would allow our Group to gain direct access to capital markets for equity and/or debt financing to fund its existing operations and future expansion without reliance on the WXB Group, thereby improving its operating and financial management efficiencies," the company said in a filing.
In a separate announcement, Wuxi Biologics said it would own in aggregate of about 50.91% stake in Wuxi XDC, if the spin-off is successful.
The offer price for the unit's spinoff under the global offering is expected to range between a minimum and maximum price of HK$19.90 per share and HK$20.60 per share, respectively, Wuxi Biologics said.
The company said the unit was expected to have a market capitalization of between HK$23.45 billion and HK$24.28 billion.
https://www.yahoo.com/news/wuxi-biologics-medical-research-unit-224107332.html
Abcam shareholders approve $5.7 billion Danaher deal
Abcam shareholders on Monday approved the proposal from Danaher Corp to acquire all outstanding shares of the company for $24 per share in cash.
Danaher agreed to buy Abcam in September in a $5.7 billion all-cash deal, including debt, in a bid to expand its portfolio of products and services.
Abcam founder Jonathan Milner had said at the time he would vote against the acquisition of the company, as the offer price undervalues the protein consumables maker.
Milner, who served as Abcam's CEO from 1999 to 2014 and later as deputy chairman from 2015 to 2020, had appealed to shareholders in June to elect him as executive chairman, while calling for the removal of Peter Allen, Michael Baldock and Sally Crawford as directors of the company.
Cambridge, England-based Abcam manufactures and supplies so-called protein consumables such as antibodies and reagents used for medical research.
https://www.yahoo.com/news/abcam-shareholders-approve-5-7-211413589.html
Subscribe to:
Comments (Atom)